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Introduction: The use of inhaled corticosteroids (ICS) in COPD may be associated with an
increased risk of pneumonia. Little is known of this risk in newly diagnosed COPD patients.
The objective of this study was to determine if the use of ICS among newly diagnosed COPD
patients is associated with an increased risk of pneumonia hospitalizations.
Methods: Using data from the Department of Veterans Affairs and Centers for Medicare and
Medicaid Services, a nested caseecontrol study was performed. We identified patients 65 years
of age or older with a new diagnosis of COPD from 1998 to 2002. A total of 145,586 patients
were identified. Cases were defined based on hospitalization for pneumonia and exposure
was prior use of ICS. Up to 10 controls were matched for each case based on age, sex, month
and year of the case. The association between ICS use and pneumonia was evaluated with
conditional logistic regression controlling for age, comorbidities, medication classes associated
with the risk of pneumonia, and markers of COPD severity.
Results: There were 13,995 cases of pneumonia. The cohort was predominantly male with an
average age of 75.1 (SDZ 5.4) years. The rate of pneumonia was 6.4 per 100 person-years.
After adjustment for covariates, patients with current use of ICS were 1.38 (95% CI,
1.31e1.45) times more likely to have a hospitalization for pneumonia than those without
current use of ICS.St. M/C 719, Chicago, IL 60612-7323, USA. Tel.: þ1 312 996 8039; fax: þ1 312 996 4665.
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increased risk of hospitalization for pneumonia.
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Inhaled corticosteroids (ICS) are used by a large proportion
of patients with chronic obstructive pulmonary disease
(COPD),1e4 however, the role of ICS in the treatment of
COPD continues to evolve. Although clinical studies have
shown improved outcomes such as decrease in acute
exacerbations of COPD with the use of ICS,5e10 more
recently, ICS use in COPD has also been associated with an
increase in the rate of pneumonia.7,8,10,11
The Towards a Revolution in COPD Health study found
a significant increase in the rate of pneumonias in those
receiving fluticasone alone (18.3%) and those receiving
fluticasone and salmeterol in combination (19.6%)
compared to placebo (12.3%).7 Other studies evaluating the
effect of fluticasone and salmeterol, in combination, versus
salmeterol alone or tiotropium alone on COPD exacerba-
tions also found an increase in the rate of pneumonia in the
fluticasone containing regimen.8,10,11 In a recent Canadian
study using health databases to evaluate the risk of pneu-
monia hospitalizations and the use of ICS in pneumonia,
there was a 1.7-fold increase in the rate of pneumonias in
those receiving ICS.12 Meta-analyses to assess the effects of
ICS on the risk of pneumonia in COPD patients have shown
conflicting results. A meta-analysis evaluating the risks and
benefits of adjunctive ICS therapy in severe/very severe
COPD also found an increased risk of pneumonia in those
receiving ICS (RR, 1.68, 95% CI 1.28e2.21).13 Another meta-
analysis to determine adverse events in patients with stable
COPD compared to nonsteroid inhaled therapy found that
patients receiving ICS therapy had a relative risk of pneu-
monia of 1.34 (95% CI, 1.03e1.75).14 However, the most
recent meta-analysis evaluating the use of a specific ICS,
budesonide, for up to 12 months only did not show
increased risk of pneumonia in patient with COPD.15
Unlike asthma, where ICS has an established role, the use
of ICS in COPD is becoming more unclear. The reduction in
acute exacerbations of COPD with the use of ICS has been
questioned due to improper statistical techniques used in
studies to come to this conclusion.16,17 To help clarify the
role of ICS,we need to better understand the risks associated
with its use in various COPD populations, especially as it
relates to serious pneumonias that require hospitalization.
Those with newly diagnosed COPD are likely to have more
limited long-term exposure and possibly less severe disease.
Understanding the risk to benefit ratio of ICS in this pop-
ulation is essential prior to recommending and/or initiating
therapy with ICS. The objective of this study was to deter-
mine if the use of ICS among newly diagnosed COPD patients
is associated with an increased risk of serious pneumonias.
Methods
This study was approved by the Institutional Review Board
at the Hines VA Hospital, Jesse Brown VA Medical Center,
and the University of Illinois at Chicago.Study design and cohort
We conducted a nested caseecontrol study in a cohort of
Veterans Affairs (VA) patients with COPD. VA administra-
tive data was used to identify patients 65 years of age or
older with a diagnosis of COPD (ICD-9 codes 491.x, 492.x,
496) from October 1, 1998 to September 30, 2002. The
date of diagnosis or entry date was defined as the
following: (1) the discharge date of a hospitalization with
COPD as a primary diagnosis, or (2) date of the second
outpatient clinic visit with a COPD diagnosis within a one
year period. To ensure that we included patients with
a new diagnosis of COPD and not those with COPD who
were new to the VA, patients also required at least one
encounter in the VA within one year prior to the entry
date. Exclusion criteria included the following: (1) a
diagnosis of COPD one year prior to the entry date to
capture new cases, and (2) a concomitant diagnosis of
asthma (ICD-9 code 493.x). Patients meeting all criteria
were followed until their first hospitalization for pneu-
monia, death, or until September 30, 2003. Once the
patients to be included were identified, a combination of
VA administrative and Centers for Medicare and Medicaid
Services (CMS) data was used to identify the case, expo-
sure, and covariates.
Case definition and controls
A case was defined as a hospitalization with a primary
diagnosis of pneumonia (International classification of
diseases, 9th version (ICD-9) code 480.x to 486.x, and
487.0) during the follow-up period. The date of the hospi-
talization was called the event date. Death within 30 days
of the event was identified. For each case identified, up to
10 control patients matched for age (within 5 years) and sex
were selected at random from those who entered the
cohort in the same month and year as the case patient.
The control patients had to be at risk on the date of the
corresponding case and this date was defined as the event
date for the control patients.
Exposure
Exposure was defined as the use of inhaled corticosteroids
(ICS) prior to the event date. ICS included orally inhaled
beclomethasone, budesonide, flunisolide, fluticasone, and
triamcinolone. Doses were converted to beclomethasone
equivalents18 and cumulative exposure was calculated. The
average daily dose was calculated for each patient and
categorized into low (1000 mg per day), moderate
(>1000e2000 mg per day), and high (>2000 mg per day)
doses. Exposure was also categorized based on timing of ICS
exposure as well as dose of ICS exposure, and the interac-
tion between time and dose. Exposure time was divided
into 90 day interval prior to the event. Current use was
defined as use within 90 days prior to the event date.
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Covariates included were age, comorbidities, medication
classes associated with the risk of pneumonia, and severity
of COPD. Comorbidities were determined by a combination
of diagnostic codes and dispensing of prescriptions associ-
ated with particular disorders at any time from a year prior
to entry date to the event date. ICD-9 codes were used to
identify diabetes mellitus, hypertension, chronic kidney
disease, chronic liver disease, heart disease (i.e. heart
failure and coronary artery disease), cancer, alcoholism,
substance abuse, depression, mental health disorders,
dementia, and other lung diseases (i.e. cystic fibrosis with
pulmonary manifestations, pneumoconiosis, and bronchi-
ectasis). Prescription dispensing of various classes of
medication were used to identify gastrointestinal disease
(i.e. histamine antagonists, proton pump inhibitors) and
hyperlipidemia (i.e. 3-hydroxy-3-methylglutaryl-coenzyme
A reductase inhibitors).
Prescriptions of classes of medications that could be asso-
ciated with the risk of pneumonia were also included. These
included central nervous system medications (i.e. sedatives,
hypnotics, barbiturates, benzodiazepines, anticonvulsants,
and antiparkinson therapy) and immunosuppressant/disease
modifying antirheumatic drugs (i.e. cyclophosphamide,
chlorambucil, methotrexate, cyclosporine, azathioprine,
cyclosporine, tacrolimus, muromonab-cd3, anti-malarials,
antirheumatic gold compounds, sulfasalazine).
Severity of COPD was determined by a combination of
number of dispensed prescriptions of respiratory medica-
tions (i.e. short-acting b-agonists, ipratropium, long-acting
b-agonists, and theophylline) and antibiotics (excluding
those prescribed 30 days prior to the event date), average
daily dose of oral corticosteroids, count of primary care
visits, count of emergency department visits, and number
of acute exacerbations of COPD. All were measured in the
year before the event date, except oral corticosteroids
which was measured 180 days prior to the event date.
Acute exacerbations of COPD were identified using
a combination of inpatient, outpatient, and pharmacy
data. Exacerbations were defined based on the presence of
an ICD-9 code related to COPD and/or specific to an exac-
erbation (ICD-9 490, 491, 491.0, 491.1, 491.2, 491.21,
491.22, 491.8, 491.9, 492.x) with one of the following:
(1) an inpatient hospitalization; (2) an emergency depart-
ment visit; or (3) an outpatient visit with either an oral
steroid or antibiotic prescription dispensed within five days
of the visit with less than a 30 day supply. Outpatient visits
that included a diagnosis for infections other than respira-
tory infections (e.g. cellulitis) were not included as an
exacerbation. Exacerbations were assumed to last 30 days
and after 30 days a new acute exacerbation could be
identified.19,20Statistical analysis
Conditional logistic regression was used to determine the
association between ICS exposure and the risk of hospital-
ization for pneumonia in patients with COPD. Odds ratios
and 95% confidence intervals were used to quantify the risk
of hospitalization with pneumonia in adjusted andunadjusted conditional logistic regression models. Adjusted
models included the covariates listed above. Conditional
logistic regression was also used to estimate odds ratios.
Separate odds ratios were also estimated for interaction
between current use of ICS (90 days) and oral corticoste-
roids. Recent use of oral corticosteroids was defined as
having oral drugs dispensed between 31 and 90 days before
the event date, as more recent use at time of pneumonia
may be due to worsening COPD. All statistical analysis was
performed using STATA version 9.2 (StataCorp., College
Station, TX).
Sensitivity analysis
To account for chronic oral corticosteroid use as a marker
of severity of COPD, we ran a sensitivity analysis excluding
these patients. As it is sometimes difficult to discern
chronic oral corticosteroid dispensing from daily dose
prescriptions to be taken as steroid bursts, we defined
chronic oral use of corticosteroids in the following two ways
using a medication possession ratio (MPR). The MPR is the
ratio of the number of days supply of medication dispensed
over the six month time frame. A patient was considered to
be receiving chronic oral corticosteorids if six months prior
to the event, the following was noted: (1) MPR of 0.8 and
an average daily dose of 10 mg/day, and (2) an MPR of
0.5 and an average daily dose of 20 mg/day. The
conditional logistic regression model was again used
adjusting for covariates used in the original analysis.
Results
A total of 145,586 were included in the cohort. From this
cohort, a total of 13,995 cases were matched to 131,591
controls (average of 9.4 controls/case). The population was
predominantly male (casesZ 99.1%, controlsZ 99.8%) and
the average age was 75.4 (SDZ 5.6) years for the cases and
75.0(SDZ 5.4) years for the controls. The baseline char-
acteristics of the case and control subjects are shown in
Table 1. The average duration of follow-up was 1.49
(SDZ 1.11) years per person. During 217,558 person-years
of follow-up, the rate of hospitalization for pneumonia
(cases) was 6.4 cases per 100 person-years.
The average daily dose of ICS and oral corticosteroids
stratified by days prior to the event are shown in Table 2.
A total of 21.7% of case patients were exposed to ICS 90
days prior to the hospitalization for pneumonia compared
to 16.0% of the control patients (p< 0.001). The majority
of the patients using ICS 90 days prior were using low doses
(1000 mg/day). Table 3 shows the adjusted odds ratio of
hospitalization for pneumonia associated with ICS use.
After adjustment for covariates, patients with current use
of ICS (90 days) were 1.38 (95% CI, 1.31e1.45) times more
likely to have a hospitalization for pneumonia than those
without current use of ICS. A doseeresponse relationship or
a relationship based on time of use was not noted. When
stratified by time of use and dose, those with current and
low dose of ICS were most likely to be hospitalized with
pneumonia (ORZ 1.51, 95% CI 1.41e1.62). Table 4 shows
the adjusted odds ratio of hospitalization for pneumonia
associated with ICS and oral corticosteroid use. When
Table 1 Characteristics of cases of pneumonia and
matched controls.
Case
subjects
Control
subjects
Number 13,995 131,591
Age(yr), mean (SD) 75.4 (5.6) 75.0 (5.4)
Gender, % male 99.1 99.8
Comorbidities
Diabetes, % 32.2 27.9
Hypertension, % 76.0 76.9
Kidney disease, % 12.1 7.0
Liver disease, % 2.0 1.2
Heart disease % 66.1 55.2
Cancer, % 41.0 35.2
Alcohol abuse, % 5.0 3.8
Substance abuse, % 23.7 20.4
Depression, % 18.7 15.0
Mental health, % 8.0 5.2
Dementia, % 5.4 3.5
Other lung diseases, % 2.7 2.2
Central nervous system
drugs, %
15.9 11.8
Gastrointestinal drugs, % 46.3 41.3
Hyperlipidemia drugs, % 32.1 36.5
Immunosuppressive drugs, % 0.8 0.5
1 COPD exacerbation,
1 year prior, %
42.8 21.2
Mean (SD) 1.13 (2.41) 0.46 (1.49)
Antibiotic Use 1 year prior
to event, number of
prescriptions, Mean (SD)
1.11 (2.42) 0.76 (1.85)
Medication use 180 days prior to event date
LABA, % 11.5 8.7
SABA, % 52.3 41.7
IPRA, % 34.2 24.0
THEO, % 7.9 5.4
Oral corticosteroids (%) 17.1 7.9
Health care utilization
PCP visits, mean (SD) 7.0 (7.8) 6.4 (7.0)
ED visits, mean (SD) 0.7 (1.9) 0.3 (1.3)
Hospitalizations, mean (SD) 1.1 (1.6) 0.4 (1.0
LABA, long-acting bronchodilators; SABA, short-acting bron-
chodilators; IPRA, ipratropium; THEO, theophylline; PCP,
primary care visits; ED, emergency department visits.
Table 2 Oral and inhaled corticosteroid use prior to date
of hospitalization for pneumonia or day at risk for
pneumonia.
Cases Controls p-Value
ICS use
Average daily
dose, mg/day,
mean (SD)
90 days 344.4 (989.0) 265.3 (879.9) <0.001
91e180 days 155.6 (471.0) 124.0 (425.7) <0.001
181e270 days 93.5 (303.5) 75.5 (268.0) <0.001
271e365 days 65.9 (219.5) 52.9 (195.0) <0.001
1 year 213.7 (556.9) 168.1 (503.9) <0.001
Oral steroid
use, mean (SD)
No. of prescriptions,
90 days
0.3 (0.8) 0.1 (0.5) <0.001
No. of prescriptions,
91e180 days
0.1 (0.5) 0.1 (0.4) <0.001
Ave daily
dose (mg/day),
31e90 days
1.2 (5.4) 0.4 (3.1) <0.001
Ave daily
dose (mg/day),
91e180 days
0.7 (4.3) 0.3 (1.8) <0.001
Cumulative dose
(mg), 31e90 days
108.6 (487.0) 38.8 (278.5) <0.001
Cumulative dose
(mg), 91e180 days
123.2 (782.0) 45.6 (331.1) <0.001
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with current use of inhaled and oral corticosteroids were
the most likely to have a hospitalization for pneumonia
(ORZ 1.70, 95% CI 1.51e1.90). Association of pneumonia
and oral corticosteroids was stronger than with ICS alone
and the recent use of both had a stronger relationship then
the use of one alone. However, after excluding those with
chronic oral corticosteroids use, the OR was 1.39 (95% CI
1.19e1.62) after excluding those with an MPR 0.8 and
average daily dose 10 mg/day and 1.43 (95% CI,
1.22e1.66) after excluding those with an MPR 0.5 and
average daily dose 20 mg/day.In those hospitalized with pneumonia, 16.4% died within
30 days of being hospitalized (nZ 2290). The 30 day
mortality for those with current use of ICS was 13.3% and
for those without current use of ICS was 17.2% (p< 0.001).
The 30 day mortality for those with current use of oral
corticosteroids was 19.8% and for those without current use
was 15.9% (p< 0.001).
Discussion
We found that within a cohort of patients with newly
diagnosed COPD, the current use of ICS was associated with
an increased risk of being hospitalized for pneumonia. This
finding is consistent with prior studies.7,10,12,13 However,
our study was unique in evaluating this association in
patients with a recent diagnosis of COPD, thus a limited
long-term exposure to corticosteroid agents. This may
explain the lack of a doseeresponse relationship that was
seen in the study by Ernst et al.12 Most of the patients
receiving ICS in our study, were receiving doses equivalent
to beclomethasone <1000 mg/day (equivalent to flutica-
sone <500 mg/day), whereas in the Ernst et al. study, the
majority of the patients were receiving doses equivalent to
fluticasone 500e999 mg/day possibly indicating more mild
disease in our cohort.
The meta-analysis by Sin et al. did not find an increased
risk of pneumonia in those using inhaled budesonide for
COPD. However, the observation period was relatively short
at one year compared to other studies. The study duration
Table 3 Unadjusted and adjusted odds ratios of hospitalizations for pneumonias associated with inhaled corticosteroid use.
Cases (%) Controls (%) Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Number 13,995 131,591
ICS use
No use in past year 70.5 77.7 1.00 1.00
Current use (last 90 days) 21.7 16.0 1.51 (1.45e1.58) 1.38 (1.31e1.45)
Low dose (1000 mg/day) 9.0 6.0 1.66 (1.56e1.77) 1.51 (1.41e1.62)
Medium dose (>1000 to 2000 mg/day) 5.4 4.3 1.40 (1.29e1.52) 1.28 (1.18e1.39)
High dose (>2000 mg/day) 7.3 5.7 1.43 (1.34e1.53) 1.30 (1.21e1.41)
Past use, %
91e180 days 3.4 2.8 1.32 (1.20e1.46) 1.21 (1.09e1.34)
181e270 days 2.5 1.9 1.48 (1.32e1.65) 1.39(1.23e1.56)
271e365 days 1.9 1.5 1.36 (1.20e1.55) 1.31 (1.14e1.50)
Use and dose
Current use and low dose (90 days, 1000 mg/day) 9.0 6.0 1.66 (1.56e1.77) 1.51 (1.41e1.62)
Current use and high dose (90 days, >1000 mg/day) 12.7 10.0 1.42 (1.34e1.50) 1.29 (1.22e1.37)
Past use and low dose (91e365 days, 1000 mg/day) 5.6 4.5 1.37 (1.27e1.48) 1.27 (1.17e1.38)
Past use and high dose (91e365 days, >1000 mg/day) 2.2 1.7 1.39 (1.23e1.57) 1.31 (1.15e1.49)
250 M.J. Joo et al.and follow-up in the other meta-analyses were 6e40
months14 and 6e36 months.13 Due to the seasonal variation
in the incidence of community acquired pneumonia
a longer follow-up period may have noted more cases of
pneumonia.21 The average years of follow-up per person, or
time to pneumonia, was 1.49 years in our study with the
endpoint being pneumonia hospitalization, death, or one
year after the final date of the inclusion period. This would
have resulted in various follow-up periods for those with
pneumonia. However, the controls were matched on date
of entry and assigned the same end date as the case and
therefore would have similar follow-up time. Therefore,
the risk of pneumonia in terms of observation time included
in the analysis would be similar between cases and
controls.’’
Similar to other studies, our study did not find an
increased risk of death in those using ICS.13,14 Our study
showed lower 30 day mortality in those receiving current
ICS compared to those not receiving current ICS. This may
suggest that pneumonia associated with the use of ICS may
be less severe than pneumonia not associated with ICS
use.21 ICS, which can increase risk of pneumonia, may also
decrease severity of the pneumonia by decreasing the level
of inflammation. An alternative explanation may be that
those using ICS may have better COPD disease control at the
time of the pneumonia diagnosis. Future studies are needed
to further refine this relationship.
A major strength of our study is the large number of
cases and more complete healthcare information as data
from CMS was included. As U.S. veterans over the age of 65
qualify for Medicare benefits from the government in
addition to VA benefits, care may be provided outside of
the VA Healthcare system. Hospitalization for pneumonia
may be urgent or emergent with use of the closest medical
facility, which may not be a VA hospital. CMS data allows up
to capture this health care utilization outside of the VA.At baseline, the case patients appeared to have more
severe respiratory disease compared to the control patients
as evidenced by a larger proportion having an acute COPD
exacerbation, using respiratory medications and having at
least one dispensing of oral corticosteroids, and having
increased health care utilization prior to the pneumonia
hospitalization. To address the possibility of confounding by
indication, we adjusted for these differences in the
severity of disease. We also conducted a sensitivity analysis
excluding those who were considered chronic oral cortico-
steroid users. Aside from the severity of disease, comor-
bidities and other risk factors for pneumonia were
accounted for by ICD-9 codes as well as specific pharma-
ceutical agents that could be associated with pneumonia.
After these adjustments and sensitivity analysis, there was
still an independent association between the risk of pneu-
monia and current use of ICS.
Our study does have some limitations. First, similar to
previous studies the diagnosis of pneumonia; we could not
radiographically confirm a diagnosis of pneumonia.
However, not all cases of pneumonia requiring pharmaco-
therapy are evident on chest radiographs as evidenced by
studies comparing high resolution computed tomography
and chest radiographs22 and laboratory evaluations in those
with clinical or radiographic diagnosis of pneumonia.23 In
addition, it seems unlikely that a patient hospitalized with
a diagnosis of pneumonia would not have a confirmatory
test by way of chest radiographs or computed tomography.
Our definition was a hospitalization with a primary diag-
nosis of pneumonia. Second, the medication data is indic-
ative of medication dispensed and not necessarily used.
Third, assessment of lung function was not used in the
diagnosis of COPD. To strengthen the likelihood of COPD,
we included patients hospitalized with a primary diagnosis
of COPD or those with at least two outpatient visits for
COPD. Fourth, we did not have smoking histories and the
Table 4 Unadjusted and adjusted odds ratios of hospitalizations for pneumonias associated with inhaled and oral cortico-
steroid use.
Cases (%) Controls (%) Unadjusted OR Adjusted OR
Number 13,995 131,591
() Oral steroids (31e90 days),
() ICS (90 days)
71.2 80.8 1 1
() Oral steroids (31e90 days),
(þ) ICS (90 days)
17.7 14.4 1.42 (1.35e1.48) 1.37 (1.30e1.44)
(þ) Oral steroids (31e90 days),
() ICS (90 days)
7.1 3.2 2.57 (2.39e2.76) 1.64 (1.50e1.80)
(þ) Oral steroids (31e90 days),
(þ) ICS (90 days)
4.0 1.6 2.84 (2.58e3.12) 1.70 (1.51e1.90)
() Oral steroids (31e180
days), () ICS (90 days)
69.0 79.4 1 1
() Oral steroids (31e180
days), (þ) ICS (90 days)
16.6 13.8 1.41 (1.35e1.48) 1.38 (1.31e1.45)
(þ) Oral steroids (91e180
days), () ICS (90 days)
2.1 1.4 1.79 (1.59e2.02) 1.25 (1.10e1.43)
(þ) Oral steroids (91e180
days), (þ) ICS (90 days)
1.1 0.7 1.87 (1.58e2.21) 1.26 (1.05e1.52)
ICS use and pneumonia in COPD 251possibility remains that our associations are confounded by
tobacco use. Finally, although we controlled for severity
using measured data, there is the potential for confounding
based on unmeasured variables.
In conclusion, we found an increase in the risk of
hospitalization for pneumonia associated with the use of
ICS in patients with newly diagnosed COPD. We did not find
an increased rate of death from pneumonia related to
current ICS use. The risk of severe pneumonia should be
considered when starting even low doses of ICS in patients
with a recent diagnosis of COPD.Acknowledgements
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